The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein τ (PHF-τ; MAPT) aggregation inhibitors.
Waverley Pharma Inc. has discovered substituted (3-hydroquinazolin-4-one) derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors and thus potentially useful for the treatment of cancer.
Shanghai Meiyue Biotech Development Co. Ltd. has patented heterocyclic derivatives acting as KIT (c-KIT) inhibitors. They are reported to be useful for the treatment of autoimmune, metabolic disease, cancer, diabetes, fibrosis, urticaria, inflammatory and respiratory disorders, among others.
In handing a win to Regenxbio Inc., the U.S. Court of Appeals for the Federal Circuit also cleared some leaves from the 101 patent eligibility threshold after years of Supreme Court decisions cluttering the passageway.
Insilico Medicine Inc. has identified new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of atherosclerosis, coronary heart diseases, dementia, diabetes, hypertension, obesity, hyperlipidemia and cerebral infarction.
Haisco Pharmaceutical Group Co. Ltd. has synthesized new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of inflammatory bowel disease and psoriasis.
Augustine Therapeutics NV has divulged thiomethyl carbonyl compounds acting as histone deacetylase 6 (HDAC6) and/or HDAC1 and/or HDAC3 inhibitors. They are reported to be useful for the treatment of inflammatory disorders, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
RSS
